The Clinical Therapeutic Effectiveness of Trimetazidine in the Treatment of Patients with Dilated Cardiomyopathy

Objective To probe into the clinical therapeutic effectiveness of trimetazidine in the treatment of dilated cardiomyopathy(DCM) associated with moderate to severe chronic congestive heart failure(CHF). Methods 40 patients with DCM associated with moderate to severe chronic congestive heart failure were randomly divided into 2 groups: the control group(n=19) and the trial group(n=21).Patients of the control group were routinely treated with digitalis,diuretics,converting enzyme inhibitor,β-receptor blocker etc..On the basis of the routine treatment,patients of the trial group were given each additionally 20 mg of trimetazidine PO,t.i.d..The course of treatment lasted 8 weeks.The grade of cardiac function,left ventricular ejection fraction(LVEF),left ventricular end-distolic diameter(LVDd)and the serum level of brain natriuretic peptide(BNP) were determined before and after the 8 week treatment in patients of both groups. Results The grade of cardiac function in patients of the trial group was greatly improved after the trimetazidine treatment.The overall effective rate in patients of the trial group was 90.5% while that in those of the control group was 52.6%(P0.05).In patients of the trial group,the LVEF was dramatically increased,the LVDd greatly reduced,and the serum level of BNP significantly elevated after the treatment.However,the blood pressure and heart rate showed no apparent changes in patients treated with trimetazidine. Conclusion Trimetazidine was shown to have good therapeutic effects in the treatment of patients with DCM associated with congestive heart failure.